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Introduction
Metabolic abnormality can occur due to a range of genetic or 
acquired disorders including diabetes and obesity.1 These dis-
orders involve a disturbance of metabolomics involved in 
energy balance regulation.2 Unfortunately, the prevalence of 
obesity and related type 2 diabetes mellitus (T2DM) is consist-
ently increasing.3 The underlying pathophysiological feature of 
T2DM, and other related forms of diabetes, is primarily associ-
ated with a loss in function and/or mass of insulin secreting 
beta-cells (β-cells) of the endocrine pancreas.4 The pancreas is 
situated behind the peritoneum and consists of a head, body, 
and tail that is close to the duodenum. Most pancreatic mass 
(90%) is made of exocrine cells grouped in lobules and sepa-
rated by connective tissue.5 The product of exocrine cells, an 
alkaline liquid concentrated with digestive enzymes, is drained 
via a pancreatic duct and enters the small intestine to aid diges-
tion.6 However, throughout the exocrine tissue clusters of 
endocrine cells called ‘islets of Langerhans’ exist, these islets are 
known to play a vital role in controlling metabolism, and espe-
cially blood glucose equilibrium (Figure 1).7 The main hor-
mones secreted from pancreatic islet cells are glucagon from 
alpha (α) cells, insulin from β-cells, somatostatin from delta 
(Δ) cells and pancreatic polypeptide (PP), with release believed 
to be under strict endocrine, paracrine, and neuronal control.8 
However, several nonclassical islet peptides have also been 
described and shown to possess similarly important effects on 
islet function (Table 1). This is epitomised by recent acceptance 
of ghrelin as an islet-derived peptide secreted from epsilon (ε) 
cells with established intra-islet actions,9 as well as effects on 
metabolism beyond the pancreas.10 As such, although much 
research on pancreatic islets and T2DM treatments has focused 
on the classic peptide hormones,11 the role and therapeutic 
applicability of nonclassic islets peptide hormones also needs 
to be considered.
Classical Islet Peptides
As noted above, the endocrine pancreas secretes 5 peptide 
hormones, namely, glucagon, insulin, somatostatin, PP, and 
ghrelin, from specific cell types, that play a critical role in glu-
cose homeostasis and energy metabolism8 (Table 1). A secre-
tory interplay between glucagon and insulin balances blood 
glucose in healthy individuals.12 Glucagon is released in times 
of low glucose to promote hepatic glycogenolysis,13 whereas 
insulin is released in response to raised glucose to promote 
glycogenesis and lipogenesis.14 The underlying molecular pro-
cesses of insulin exocytosis in response to glucose is well 
known and involves the closure of KATP channels, β-cell mem-
brane depolarisation, calcium influx, and subsequent secretion 
of insulin.15 During the onset of diabetes this relationship is 
negatively affected and insulin secretion rates decrease,16 this 
is often combined with desensitisation of the insulin receptor 
(IR) located on peripheral tissues.17 As such, treatment of dia-
betes has focused predominantly on addressing the deficit in 
insulin secretion through administration of direct insulin 
secretagogues or insulin replacement therapy,18 as well as ther-
apies aimed at resensitising the IR. In this regard, there are a 
variety of nonclassical islet peptides that can trigger or poten-
tiate insulin secretion, improve β-cell survival or increase insu-
lin sensitivity through modulation of G-protein coupled 
receptors (GPCRs)8 (Figure 1).
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Nonclassical Islet Peptides – Pancreatic Effects
Incretin and related peptides
As well as the classical islet peptides, there are a number of 
other peptide hormones known to be synthesised and released 
within pancreatic islets, often termed ‘nonclassical’ islet pep-
tides8 (Figure 1). The incretin hormones, namely glucagon-like 
peptide (GLP)-1 and glucose dependent insulinotropic peptide 
(GIP), are the most comprehensively studied nonclassical islet 
peptides.19 Typically, GLP-1 and GIP are considered to be 
endocrine L- and K-cell derived peptides released in response 
to nutrient ingestion.20 Elegant studies have described the 
secretory dynamics of these 2 hormones from the gut.21 
However, both GIP and GLP-1 have also been shown to be 
synthesised and released locally within pancreatic islets, with 
important paracrine effects.22 Glucagon-like peptide-1 has 
direct and indirect actions on α-cells, directly inhibiting gluca-
gon23 and indirectly increasing intra-islet regulation via soma-
tostatin,24 GIP effects on glucagon are glucose dependent. As 
such, at low levels of glycaemia, glucagon release is increased by 
GIP with minimal effect on insulin, with this glucagonotropic 
effect disappearing at higher glucose levels.25 Mechanistically, 
GLP-1 and GIP potentiate insulin secretion by binding to spe-
cific GPCRs located on pancreatic β-cells to increase cAMP26 
and activate Epac and protein kinase A (PKA).20 The process of 
GIP and GLP-1 induced insulin secretion is well described, 
primarily due to increased interest in the ‘incretin effect’ over 
the past decades, clearly defining how the intestinally released 
hormones potentiate insulin release following meals.27 These 
mechanisms supplement glucose-mediated effects, closing 
K+ATP and Kv channels and promoting depolarisation of the 
β-cell. Calcium channels are also sensitised via PKA and Epac.20 
Together this facilitates intracellular calcium stores to be 
released, resulting in insulin secretion. Glucagon-like peptide-2 
(GLP-2) is another proglucagon derived peptide, its principle 
role is to maintain intestinal mucosal villus epithelium and aid 
gut absorption.28 In addition, GLP-2 acts as an intestinal 
growth factor, with clinical application for short bowel syn-
drome.29 Glucagon-like peptide-2 receptors are expressed on 
rodent α-cells 30 and linked to increased glucagon secretion.31 
Notably, GLP-2 also has been demonstrated to possess prolif-
erative and anti-apoptotic effects in β-cells,32 highlighting a 
role in glucose homeostasis. However, GLP-2 has no effect on 
insulin secretion from β-cells, or isolated mouse islets.31
Peptide Tyrosine Tyrosine
Peptide Tyrosine Tyrosine (PYY) is a 36 amino acid peptide hor-
mone best known as being released postprandially from enter-
oendocrine L-cells, similar to GLP-1.33 Moreover, both hormones 
are expressed within pancreatic islets and released locally (Figure 
1).34 Peptide Tyrosine Tyrosine and neuropeptide Y (NPY) both 
Figure 1. Endocrine pancreatic cell types and their peptide secretions. Exocrine pancreatic acinar cells constitute most of the pancreatic tissue, these 
cells produce digestive enzymes which are transported via the pancreatic ducts. The endocrine pancreas is illustrated with all cell types; alpha, beta, 
delta, PP, and epsilon. The cells are arranged in compact islets and secrete a number of classical and ‘nonclassical’ peptides, as depicted. PP indicates 
pancreatic polypeptide.
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activate neuropeptide Y receptors (NPYRs) and represent prom-
ising antidiabetes targets.34 Although the peptides activate the 
same family of receptors, their effects on islet secretions differ due 
to differences in receptor affinity and specificity. Early rodent 
studies indicated plasma insulin levels were reduced or unaffected 
by PYY.35 Further studies in isolated islets and human β-cells 
also revealed minimal effect of PYY on insulin secretion, although 
β-cell anti-apoptotic and proliferative effects were noted.36 As 
such, transgenic mouse models overexpressing PYY exhibited 
enhanced glucose facilitated insulin responses and amplified islet 
number.37 Consistent with these findings, knock out of PYY in 
the gut and pancreas causes disruption of islet morphology and 
decreased β-cell mass.38 In addition, streptozotocin-induced 
insulin deficiency and β-cell destruction is linked to reduced islet 
PYY levels, whereas hydrocortisone-induced increases of β-cell 
mass are linked to elevated PYY levels.36 Furthermore, in the 
developing foetal pancreas PYY is detectable at a very early 
stage,39 indicating potential effects on pancreatic islet develop-
ment. For PYY effects, it is also important to note the distinct 
receptor specificity of the 2 main circulating molecules and pan-
creatic expression of these receptors. As such, PYY (1-36) binds 
and activates all NPYRs,40 whereas PYY (3-36) is an NPYR2-
specific molecule. PYY can prevent glucagon release from iso-
lated islets, although NPY receptors are thought to be specifically 
Table 1. Classical and ‘nonclassical’ peptides secreted by the pancreas. Table includes the peptides main origin tissue (including gut and CNS) and 
cells of origin. The key secretory initiators are stated and the effect each peptide has on the pancreatic islet.
PEPTIDE ORIgIN REgULATION OF SECRETION EFFECTS ON ISLET
CLASSICAL TISSUE CELL  
 Insulin Pancreas β-cell Plasma glucose, FFA, glucagon Inhibits glucagon
 glucagon Pancreas α-cell Amino acids released by digestion Stimulates insulin secretion
 Somatostatin Pancreas Δ-cell glucagon Inhibits release of insulin and 
glucagon
  Pancreatic 
polypeptide
Pancreas PP-cell To be determined Inhibits insulin
 ghrelin Pancreas epsilon cell Dietary intake of nutrients Inhibits insulin
Nonclassical
 gLP-1 Pancreas/gut α-cell/Intestinal L-cell Ingested glucose load Increases insulin secretion, β-cell 
mass, inhibits glucagon, apoptosis
 gLP-2 Pancreas/gut α-cell/L-cell Dietary intake of nutrients Positive effects on β-cell proliferation 
and apoptosis
 gIP Pancreas/gut α-cell/Intestinal K-cell Ingested glucose load Causes insulin secretion, and β-cell 
proliferation
 PYY Pancreas/gut α-cell/Intestinal L-cell Dietary intake of nutrients β-cell proliferative and anti-apoptotic 
effects
 gastrin Pancreas/gut β-cell/g-cell Stomach distension, digested 
proteins
Causes insulin secretion
 CCK Pancreas/gut β-cell/EEC cell Stomach distension, digested 
proteins
β-cell proliferative and anti-apoptotic 
effects
 Xenin-25 Pancreas/gut Islets/K-cell Dietary intake of nutrients Increases gIP-mediated insulin 
secretion
 Secretin Pancreas/gut β-cell/S-cells Dietary intake of nutrients/
Stomach acid
Inhibits glucagon
 Urocortin3 Pancreas α-cell/β-cell Plasma glucose (co-secreted with 
insulin)
Promotes insulin secretion
 Amylin Pancreas β-cell Dietary intake of nutrients Inhibits insulin secretion and β-cell 
proliferation
 Vasopressin Pancreas/CNS β-cell/M-cell Response to hypertonicity Promotes Insulin secretion, β-cell 
proliferative and anti-apoptotic effects
 Oxytocin Pancreas/CNS β-cell/M-cell Related to reproductive function Promotes insulin secretion, β-cell 
proliferative and anti-apoptotic effects
Abbreviations: CCK, cholecystokinin; CNS, central nervous system; EEC, enteroendocrine cells; FFA, free fatty acid; gIP, glucose dependent insulinotropic peptide;  
gLP, glucagon-like peptide; PYY, Peptide Tyrosine Tyrosine.
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on β-cells.41 This would suggest PYY modulation of glucagon 
occurs via indirect pathways and could involve insulin or somato-
statin release.42 The ability of PYY to restore deranged insulin 
and glucagon secretions in T2DM, is of clinical significance and 
these findings justify further investigation.43 Similar to PYY, the 
neurotransmitter NPY has also been linked to decreased insulin 
and glucagon release.44,45
Gastrin and cholecystokinin
Receptors for gastrin and cholecystokinin (CCK), namely 
CCK1 receptors, are highly expressed on α- and β-cells and 
both are synthesised and secreted by islets and effect islet func-
tion.46 Hypergastrinaemia is linked to excessive insulin produc-
tion and low blood glucose,47 and both hormones induce 
secretion with or without glucose.48 There is conflicting evi-
dence on the effect of gastrin on glucagon secretion, with some 
models highlighting a stimulatory effect 49 whereas others con-
flict these findings.50 Disruption of the gastrin gene in mice 
does not affect islet morphology or basal glucagon levels, but 
does cause substandard glucagon secretion in response to insu-
lin caused hypoglycaemia.51 Gastrin in combination with epi-
dermal growth factor has been found to cause β-cell regeneration 
in mice after near total destruction by alloxan.52 In respect to 
CCK, little effect on glucagon release has been recorded,53 but a 
close relationship to GLP-1 has been identified.54 Research has 
focused on an intra-islet loop based on local islet secretion of 
these peptides, whether GLP-1 and CCK originating from the 
gut have the same islet effects is unknown. Sulphation of CCK 
at a tyrosine located 7 residues from the C-terminus is crucial 
for CCK bioactivity,55 this post-translational modification 
allows for strengthened protein-protein interaction.56 
Glucagon-like peptide-1 secreted from the α-cell targets the 
β-cell to stimulate CCK production, while CCK can also stim-
ulate α-cells to release GLP-1 increasing β-cell survival and 
proliferation, in a positive feedback loop within β-cells.54,57 
Mechanistically, CCK1 receptor stimulation phosphorylates 
PKA and phospholipase C (PLC) increasing intracellular cal-
cium concentrations via the L-channel, this causes positive bias 
on PLC activity. Increased calcium and diacylglycerol produced 
by PLC activates protein kinase C58 which ultimately opens 
gated calcium channels.59 Further work is required to fully 
assess the therapeutic promise of both gastrin and CCK, espe-
cially in relation to potential off-target side effects.47
Urocortin3 and islet amyloid polypeptide
Urocortin3 (Ucn3) is a peptide hormone expressed by mature β-
cells, early work revealed insulin and glucagon release to increase 
in response to Ucn3 treatment.60 Interestingly, Ucn3 may also 
have benefits on plasma glucose61 and glucose tolerance.60 This 
has driven new studies to define the physiological role of Ucn3, 
and it is known that Ucn3 amplifies somatostatin release to mod-
ulate insulin and glucagon secretion.62 Somatostatin receptors 
(SSTRs) have been acknowledged on α- and β-cells.63 Rodent 
studies reveal inhibition of glucagon and insulin is facilitated 
through SSTRs 5 and 2, respectively; knockout of these receptors 
results in variation of basal and glucose stimulated insulin sec-
tion.64 In T2DM, Ucn3 expression is reduced in β-cells and 
causes an unstable glycaemic state.65 Islet amyloid polypeptide 
(IAPP, amylin) is a peptide co-secreted from β-cells with insulin 
in response to glucose and fatty acids at a ratio of 15:1 
(insulin:amylin).66 Currently, 3 amylin receptors have been iden-
tified, namely AMY1, AMY2, and AMY367 and activation by 
amylin is thought to regulate insulin secretion under certain dis-
ease states or conditions.68 Knockout studies in β-cells have 
revealed reduced amylin causes increased glucose-induced insulin 
secretion, whereas treatment of amylin at physiological levels 
inhibits insulin secretion.69 Amylin also controls β-cell prolifera-
tion in a glucose dependent manner. As such, at high glucose con-
centrations amylin inhibits proliferation and at low levels 
promotes β-cell proliferation.70
Xenin-25 and neurotensin
Xenin-25 is a peptide hormone traditionally characterised as 
being secreted from endocrine K-cells with GIP,71 but xenin-25, 
as well as the related neurotensin hormone, have also been found 
in pancreatic islets, alongside neurotensin receptors (NTSRs).72 
The main pancreatic effects of xenin include increasing PP 
secretion and amplifying the effects of GIP,73 indirectly effecting 
insulin and glucagon release. Xenin-25 interacts with acetylcho-
line signalling pathways to increase β-cell insulin secretion, and 
this is thought to be independent of NTSRs.74 This may explain 
slight differences in the pancreatic effect of xenin-25 and neu-
rotensin, despite both being NTSR ligands. Proliferation in 
rodent and human β-cells is enhanced by xenin-25 and neu-
rotensin, suggesting the peptides as promising antidiabetic 
agents.44 The signalling mechanisms involved in insulin and 
glucagon secretion for xenin-25, differ between human and 
mouse models in response to co-treatment with GIP.74 In mice, 
positive effects of co-treatment were seen under hyperglycaemic 
conditions. In humans, effects on insulin and glucagon where 
specifically recorded in patients with reduced glucose tolerance, 
but not in patients with T2DM.74 Cholinergic signalling may 
act as a regulatory mechanism to increase insulin secretion, and 
failure is thought to lead to the development of T2DM.75 In 
mice, atropine treatment inhibited the effect of xenin on GIP-
mediated insulin and glucagon secretion implicating cholinergic 
signalling73 whereas in humans there is no inhibition.74
Vasopressin, oxytocin, and secretin
Vasopressin (AVP) and oxytocin (OT) are neuropeptides and 
components of a cohesive system,76 with synthesis also evi-
denced within the pancreas.77,78 Oxytocin receptor knockout 
(OTKO) mice have increased sensitivity to AVP79 and AVP 
causes a significant concentration dependent increase of insulin 
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secretion in rodent (BRIN BD11) and human (1.1B4) β-
cells,77 but has no effect on glucagon secretion. AVP receptors; 
V1a, V1b, V2 are highly abundant on β-cells and antagonism 
of V1a, V1b has a negative effect on AVP-mediated insulin 
secretion.77 AVP also has positive effects on β-cell proliferation 
and survival.77 Oxytocin (OT) is known to stimulate insulin 
and glucagon secretion and have positive effects on insulin 
action, glucose intolerance and islet hypertrophy.78 Calcium-
calmodulin kinase (Ca-CAMKK), phosphoinositide-3-kinase 
(PI3K) and AMP-activated protein kinase (AMPK) pathways 
may mediate these effects80 and serotonin (5-HT) and dopa-
mine may have supplementary properties.76 Secretin is pro-
duced in the duodenum by S-cells and in the pancreas by 
secretin producing islets,81 it consists of 27 amino acids with a 
sequence similar to glucagon and GIP.82 Following an oral glu-
cose load, secretin maintains blood glucose control through 
initiating insulin release,83 while other work has detailed sup-
pressive effects on α-cell function and glucagon release.84 
Interestingly, secretin has also been found to enhance the 
effects of CCK to increase β-cell proliferation and mass.85
Nonclassical Islet Peptides – Appetite Regulation
The peptide hormones discussed above are considered to be 
nonclassical islet peptides generated within the pancreas, that 
mediate numerous local biological actions (Table 1). However, 
as well as direct pancreatic effects, many of these hormones have 
well characterised effects outside of the pancreas, that could be 
linked to pancreatic or extra pancreatic sites of synthesis.
Glucagon-like peptide-1 has a major effect on energy bal-
ance and appetite via a complex relationship that is linked to 
centrally mediated actions.86 Physiological effects of GLP-1 
include decreased food intake, inhibited gastric emptying and 
reduced gastric motility.87 These effects are facilitated by bind-
ing to the GLP-1R and signalling the central nervous system 
(CNS) via the vagal nervous system.88 Glucagon-like pep-
tide-1 is secreted by GCG neurons, which allow direct central 
activation of the GLP-1R in the NTS of the hypothalamus. 
GCG neurons signal afferent nerves to relay satiety informa-
tion to the hypothalamus.89 Glucose dependent insulinotropic 
peptides’ physiological effects on appetite are somewhat dis-
puted, in vitro work using mouse 3T3L1 adipocytes found 
GIP increases adipogenesis,90 whereas chronically reduced 
GIP in mice attenuates weight gain.91 However, transgenic 
overexpression of GIP, as well as GIP agonist treatment in 
mice reduces obesity related traits.92 Moreover, recent clinical 
studies employing co-activation of GLP-1 and GIP receptors 
have revealed that GIP can augment the body weight reducing 
effects of GLP-1.93
As noted above, PYY circulates in distinct bioactive forms, 
with PYY (3-36) recognised as the foremost circulating PYY 
peptide postprandially. As well as pancreatic secretion, PYY is 
released from L-cells of the gut, 15 minutes after food intake, 
secretion is proportional to calories consumed.94 This would 
indicate that PYY release occurs prior to nutrients reaching the 
distal small intestine, suggesting secretion is mediated centrally. 
In addition, there is evidence of enteroendocrine PYY releas-
ing cells in the upper ileum, with studies revealing such cells 
can express multiple gut hormones,29 which may also be impor-
tant in this regard.
Rodent receptor KO studies reveal PYY (3-36) acts on the 
arcuate nucleus (ARC) in the CNS via the NPY2 receptor.94 
Activation reduces appetite by increasing POMC/α-MSH 
activity95 while suppressing NPY neurons.96 Glucagon-like 
peptide-1 administration is known to cause nausea and gastric 
complications,97 and clinical studies have revealed such side-
effects are heightened after PYY(3-36) administration,98 indi-
cating related effects on energy regulation. Although CCK 
increases gallbladder contraction, inhibits gastric emptying and 
reduces food intake,99 many of its effects on energy balance are 
due to activation of peripheral vagal afferent fibres.100 However, 
CCK is also believed to penetrate the blood brain barrier (BBB) 
to act directly in the CNS to effect appetite and digestion.101
Xenin-25 decreases food intake when administered cen-
trally,102 or peripherally at elevated doses,103 indicating action 
as a satiety factor. In animal studies, xenin-25 causes anorexia 
via activation of central NTRS1.104 This has been supported by 
work in NTSR1 KO mice, which were nonresponsive to 
xenin.105 The mechanisms involved in xenin appetite regula-
tory effects are poorly described, the extracellular signal-regu-
lated kinases signalling cascade has been implicated, but is not 
essential for feeding suppression.105 In addition, a long acting 
xenin-25 analogue, xenin-25[Lys13PAL], lacked effects on 
energy intake and body weight, but did induce significant ben-
efits on glucose homeostasis in mice.106
Oxytocin and vasopressin secretion are controlled by signals 
that regulate appetite,107 and both hormones are released 
acutely following a meal.108 Oxytocin is well established to 
influence energy balance in vivo, suppressing carbohydrate 
intake109 and promoting movement and thermogenesis.110 In 
rodent brain tissue, OT cells express IRs and glucokinase, and 
can be activated by insulin and glucose.111 Further research 
identified leptin receptors, as well as receptors allied with other 
anorectic peptides such as α-MSH, on OT producing cells.112 
Ligands of these receptors signal the NTS113 including noradr-
energic A2 cells,114 and these cells directly interact with OT 
cells.115 Other peptides, such as CCK, may support the energy 
balance effects of OT at central sites, but further studies are 
needed to elucidate exact mechanisms.
Therapeutic Potential of Multiagonist Nonclassical 
Islet Peptides
Dual agonists with nonclassical islet hormone 
components
Recent novel peptide-based approaches for the treatment of 
T2D and obesity have focused on simultaneous activation of 
multiple receptors, many of which are related to nonclassical 
islet peptide hormones116 (Table 2). Synthetic peptides acting 
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as dual or triagonists at GPCRs have been predicted to have 
positive effects on energy balance expenditure, glucose homeo-
stasis and appetite.117 Early dual compounds focused on 
GLP-1/glucagon co-agonism and activity was based on the 
naturally occurring peptide oxyntomodulin.118 Treatment 
improved maximum insulin secretion compared with 
exendin-4119 and resulted in large decreases in food intake, adi-
posity and increased lipolysis.120 Weight loss effects have been 
linked to significant leptin sensitisation121 and was successfully 
translated into phase II clinical trials.122 It has been concluded 
that these peptides have a greater effect than either single hor-
mone. MEDI0382 is a GLP-1/glucagon agonist displaying 
significant promise in numerous clinical studies, reducing fast-
ing and postprandial glucose and body weight.122 MEDI0382 
has consistently exhibited a mild adverse event profile.123 
Another dual GLP-1/glucagon agonist (SAR425899) also has 
significant clinical promise, reducing HbA1c and body weight 
over 28 days, with mild adverse events124 (Table 2).
In recent years, dual incretin agonists have been developed,125 
these have focused on manipulating GIPR and GLP-1R sig-
nalling to reduce food intake and adiposity, and promote com-
bined benefits on pancreatic β-cells.126 A novel GIP/GLP-1 
agonist (N-ac(DAla2)GIP/GLP-1-exe) activates both incretin 
receptors to cause concentration dependent insulin secretion 
from BRIN BD11 β-cells and isolated islets.127 Dual receptor 
activation results in increased weight loss and improved insulin 
sensitivity compared with mono treatment in mice.125 These 
results have been confirmed in further preclinical work and in 
clinical studies.116 In a recent Phase 2A clinical trial a GLP-1/
GIP dual agonist (NNC0090-2746) with balanced affinity for 
GLP-1R and GIPR significantly reduced HbA1c and weight 
over 8 weeks in T2D patients compared with placebo.116 
LY3298176 is a fatty acid adapted peptide with GLP-1 and 
GIP receptor activity, designed to be administered once 
weekly.128 Preclinically, LY3298176 causes glucose-dependent 
insulin secretion from islets isolated from wild-type, GIPR−/− 
and GLP-1R−/− mice, indicative of activity at both receptors.128 
LY3298176 has successfully translated preclinical findings into 
human studies, imparting meaningful enhancement of glycae-
mic control and body weight93 specifically, reducing Hba1c and 
body weight greater than a benchmark group taking Dulaglutide. 
This highlights the importance of balancing receptor interac-
tion when developing dual or triagonists.129 It is worth noting 
that there was a 30% nonresponse rate, but results would indi-
cate that dual incretin agonists are more potent than established 
mono treatments93 (Table 2).
Table 2. Dual and triagonist peptides with classical/‘nonclassical’ islet peptide components. Table includes peptide hormone components, 
compound name, main effects and relevant citation(s).
PEPTIDES hORMONE 
COMPONENTS
COMPOUND NAME MAIN EFFECTS REFERENCE
DUAL AgONISTS
gLP-1/glucagon MEDI0382 Reduces fasting and postprandial glucose/body weight 123,124
gLP-1/glucagon SAR425899 Reduces hbA1c/body weight 125
gIP/gLP-1 N-ac (DAla2) gIP/
gLP-1-exe
Increases insulin secretion/sensitivity; reduces body weight 128
gLP-1/gIP NNC0090-2746 Reduces hbA1c/body weight 117
gLP-1/gIP LY3298176 Increases insulin secretion; Reduces hbA1c/body weight 93,129
gLP-1/xenin Exendin-4/Xenin-8-gln Increases insulin secretion/gIP action, reduces appetite 131
gLP-1/gastrin ZP3022 Lowers hbA1c, improves glucose tolerance and β-cell neogenesis 132
gLP-1/PYY EP45 Lowers blood glucose, stimulates insulin secretion 133,134
Triagonists
gIP/glucagon/gLP-1 gIP-Oxm Improves glucose homeostasis, insulin secretion and body weight 135
YAg-glucagon Y1-dA2-I12-N17-V18-I27-
g28,29-glucagon
Reduces plasma glucose, food intake and body weight; increases 
plasma insulin and insulin sensitivity
136





Decreases nonfasting hbA1c, food intake. Enhances insulin levels, 
glucose tolerance
144
glugagon/gLP-1/NPY ggP817 Unvalidated (FRET analysis) 145
Abbreviations: FRET, fluorescence resonance energy transfer; gIP, glucose dependent insulinotropic peptide; gLP, glucagon-like peptide; PYY, Peptide Tyrosine Tyrosine.
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A novel GLP-1/xenin hybrid also indicated significant 
therapeutic potential in mice, increasing insulin secretion, 
reducing appetite and improving GIP action.130 A GLP-1/gas-
trin dual agonist, ZP3022, also displayed multiple antidiabetic 
effects in vivo. These included lowering HbA1c, improving 
glucose tolerance and increasing β-cell neogenesis.131 Dual 
treatment of GLP-1 and PYY led to a synergistic reduction in 
food intake.132 A recent study characterised a chimeric peptide 
(EP45) that consists of sequences from exendin-4 (Ex-4) and 
PYY(3-36), multiple organs can be targeted with this pep-
tide133 (Table 2). Fluorescence resonance energy transfer 
(FRET) assays demonstrate EP45 stimulates cAMP produc-
tion via the GLP-1R, while inhibiting cAMP production via 
the NPY2R.133 These findings would indicate EP45 potenti-
ates blood glucose lowering effects by activating GLP-1R on 
β-cells, thus triggering glucose stimulated insulin secretion and 
upregulating insulin gene expression.133 EP45 could also acti-
vate receptors centrally to affect appetite and would have rele-
vance for the treatment of T2D.
Triagonists With Nonclassical Islet Hormone 
Components
The positive results from dual agonist studies have driven the 
development of triagonists, such as GIP-oxyntomodulin (GIP-
Oxm)134 and an adapted glucagon peptide (YAG-glucagon).135 
Most recent work has focused on the incretin/glucagon system 
and triagonists have been developed to activate the GLP-1/
GIP/glucagon receptors.136 Glucagon-like peptide-1/glucose 
dependent insulinotropic peptide and glucagon independently 
stimulate complementary mechanisms in vivo to cause glu-
cose-mediated insulin secretion,137 and reductions in body 
weight and cholesterol are greater than a dose matched liraglu-
tide treatment.138,139 In a diabetic rodent model GLP1R-
GCGR-GIPR tri-agonism had beneficial pancreatic effects, 
animals displayed improved glucose tolerance and reduced ab 
libitum blood glucose, with reduced insulin levels suggesting 
improved insulin sensitivity140 (Table 2). Peptide characterisa-
tion of triple-acting entities in nonhuman primates has been 
completed by Sanofi, Novo Nordisk and Hanmi, with Novo 
Nordisk and Hanmi conducting phase 1 clinical trials.129 A 
long acting GLP-1/GIP/glucagon agonist (HM15211) has a 
unique pharmacological profile, demonstrating benefits on 
weight loss and lipid profiles, while exhibiting no risk of hyper-
glycaemia. Interestingly, in mice HM15211 has also shown 
promise in treating nonalcoholic steatohepatitis (NASH), 
fibrosis141 and alzheimers disease142 (Table 2).
Other triagonists include an enzyme resistant GLP-1/gas-
trin/xenin peptide which has antidiabetic potential in respect 
to insulin secretion and enhancement of GIP action,143 as well 
as a triagonist (GGP817) that activates the GluR, GLP-1R 
and NPY2R.144 This peptide has not been validated in vivo, 
but it is thought agonism of GluR would cause increased 
energy expenditure,145 GLP-1R activation would result in 
enhanced β-cell function and improved glucose homeostasis146 
and NPY2R agonism would suppress appetite.95
Conclusion
Signalling processes within pancreatic islets are highly compli-
cated,147,148 and our recent knowledge of an important role for 
numerous nonclassical islet peptides is these processes requires 
further detailed study. Understanding their physiology, and 
potential pathophysiology in diabetes, could open up new 
promising avenues for drug effective candidates.19 Both pre-
clinical and clinical evidence demonstrate that metabolic pro-
file can be improved by synergistic action of multiple peptide 
hormone receptor targets, many of which include nonclassical 
islet peptides.149 Such strategies hold great promise for obesity 
and related forms of diabetes, especially given the optimism 
generated through early clinical observations.
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